Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
BioPharmaceutical

Anesiva Outlines Phase III Development For Pain Candidate Adlea

This article was originally published in The Pink Sheet Daily

  • News

Executive Summary

Two Phase III trials, for pain management in total knee replacement and bunionectomy surgeries, expected to begin in first half of 2008.

You may also be interested in...



Anesiva Reports Positive Phase III Results For Zingo In Adults

Company plans to file for expanded indication in the first quarter of 2008.

Anesiva Reports Positive Phase III Results For Zingo In Adults

Company plans to file for expanded indication in the first quarter of 2008.

Anesiva CEO John P. McLaughlin: An Interview With “The Pink Sheet” DAILY (Part 2 of 2)

McLaughlin discusses starting Phase III for Adlea, competing against larger firms in the pain management space and whether Anesiva would be open to an acquisition.

Table

View full table

Topics

Tags:
BioPharmaceutical
Latest Headlines

CDER, CBER Not Seeing Hiring Slowdown Despite US FDA Warnings

Medicare Reimbursement For Part B Drugs Is 48% Above 340B Prices To Hospitals, MedPAC Finds

Drug Shortages, Inspections In Focus At US FDA Appropriations Hearing

Global Pharma Guidance Tracker – March 2024

See All
UsernamePublicRestriction

Register

PS065163

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By